Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Enhanced detection of circulating tumor DNA by fragment size analysis.

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Østrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sørensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N.

Sci Transl Med. 2018 Nov 7;10(466). pii: eaat4921. doi: 10.1126/scitranslmed.aat4921.

PMID:
30404863
2.

Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients.

Mouliere F, Mair R, Chandrananda D, Marass F, Smith CG, Su J, Morris J, Watts C, Brindle KM, Rosenfeld N.

EMBO Mol Med. 2018 Nov 6. pii: e9323. doi: 10.15252/emmm.201809323. [Epub ahead of print]

3.

Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models.

Mair R, Mouliere F, Smith CG, Chandrananda D, Gale D, Marass F, Tsui DWY, Massie CE, Wright AJ, Watts C, Rosenfeld N, Brindle KM.

Cancer Res. 2018 Nov 2. pii: canres.0074.2018. doi: 10.1158/0008-5472.CAN-18-0074. [Epub ahead of print]

PMID:
30389699
4.

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors.

Ahlborn LB, Tuxen IV, Mouliere F, Kinalis S, Schmidt AY, Rohrberg KS, Santoni-Rugiu E, Nielsen FC, Lassen U, Yde CW, Oestrup O, Mau-Sorensen M.

Oncotarget. 2018 Aug 24;9(66):32570-32579. doi: 10.18632/oncotarget.25948. eCollection 2018 Aug 24.

5.

The value of cell-free DNA for molecular pathology.

Stewart CM, Kothari PD, Mouliere F, Mair R, Somnay S, Benayed R, Zehir A, Weigelt B, Dawson SJ, Arcila ME, Berger MF, Tsui DW.

J Pathol. 2018 Apr;244(5):616-627. doi: 10.1002/path.5048. Epub 2018 Mar 12. Review.

PMID:
29380875
6.

Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.

Patel KM, van der Vos KE, Smith CG, Mouliere F, Tsui D, Morris J, Chandrananda D, Marass F, van den Broek D, Neal DE, Gnanapragasam VJ, Forshew T, van Rhijn BW, Massie CE, Rosenfeld N, van der Heijden MS.

Sci Rep. 2017 Jul 17;7(1):5554. doi: 10.1038/s41598-017-05623-3.

7.

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N.

Nat Rev Cancer. 2017 Apr;17(4):223-238. doi: 10.1038/nrc.2017.7. Epub 2017 Feb 24. Review.

PMID:
28233803
8.

Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.

El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau F, Theillet C, Mazard T, Pezet D, Mathonnet M, Ychou M, Thierry AR.

Clin Cancer Res. 2016 Jun 15;22(12):3067-77. doi: 10.1158/1078-0432.CCR-15-0297. Epub 2016 Feb 4.

9.

Circulating tumor-derived DNA is shorter than somatic DNA in plasma.

Mouliere F, Rosenfeld N.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3178-9. doi: 10.1073/pnas.1501321112. Epub 2015 Mar 2. No abstract available.

10.

Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer.

Mouliere F, El Messaoudi S, Pang D, Dritschilo A, Thierry AR.

Mol Oncol. 2014 Jul;8(5):927-41. doi: 10.1016/j.molonc.2014.02.005. Epub 2014 Mar 24.

11.

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.

Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M.

Nat Med. 2014 Apr;20(4):430-5. doi: 10.1038/nm.3511. Epub 2014 Mar 23.

PMID:
24658074
12.

Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.

Mouliere F, El Messaoudi S, Gongora C, Guedj AS, Robert B, Del Rio M, Molina F, Lamy PJ, Lopez-Crapez E, Mathonnet M, Ychou M, Pezet D, Thierry AR.

Transl Oncol. 2013 Jun 1;6(3):319-28. Print 2013 Jun.

13.

Circulating cell free DNA: Preanalytical considerations.

El Messaoudi S, Rolet F, Mouliere F, Thierry AR.

Clin Chim Acta. 2013 Sep 23;424:222-30. doi: 10.1016/j.cca.2013.05.022. Epub 2013 May 30. Review.

PMID:
23727028
14.

The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients.

Mouliere F, Thierry AR.

Expert Opin Biol Ther. 2012 Jun;12 Suppl 1:S209-15. doi: 10.1517/14712598.2012.688023. Epub 2012 May 18. Review.

PMID:
22594497
15.

High fragmentation characterizes tumour-derived circulating DNA.

Mouliere F, Robert B, Arnau Peyrotte E, Del Rio M, Ychou M, Molina F, Gongora C, Thierry AR.

PLoS One. 2011;6(9):e23418. doi: 10.1371/journal.pone.0023418. Epub 2011 Sep 6.

16.

Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.

Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, Del Rio M, Molina F.

Nucleic Acids Res. 2010 Oct;38(18):6159-75. doi: 10.1093/nar/gkq421. Epub 2010 May 21.

17.

Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats.

Arancibia S, Silhol M, Moulière F, Meffre J, Höllinger I, Maurice T, Tapia-Arancibia L.

Neurobiol Dis. 2008 Sep;31(3):316-26. doi: 10.1016/j.nbd.2008.05.012. Epub 2008 Jul 15.

PMID:
18585459

Supplemental Content

Loading ...
Support Center